 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
176 News |  |
| «12 |
- | AMG 420 / Amgen
@bradloncar AMG420 program stopped? (Twitter) - Aug 8, 2019
- |||| AMG 420 / Amgen
Just heard that $AMGN stopped their BCMA-targeted #BiTE AMG 420 program. True? Anyone with more detailed information? #AMG420 #BCMA #myeloma #mmsm @AmgenOncology @H_Einsele @MyelomaTeacher @VincentRK @AndyBiotech @NoopurRajeMD (Twitter) - Aug 8, 2019
- ||| AMG 420 / Amgen
Great discussion by @SagarLonialMD, Amrita Y. Krishnan, Thomas G. Martin, Krina K. Patel and Saad Z. Usmani about the potional of #BiTe AMG 420 in R/R Multiple #Myeloma #mmsm https://t.co/1nka4OQwaM (Twitter) - Aug 4, 2019
- |||| AMG 420 / Amgen
Clinical: AMG 420 Continues to Show Efficacy in Relapsed/Refractory Myeloma - ASH Clinical News https://t.co/skHtMVd9p6 #myeloma (Twitter) - Jul 27, 2019
- ||| AMG 420 / Amgen
ASCO 2019: New BiTE Update on AMG-420 with Dr. Luciano Costa https://t.co/MZ9FYXYH1X via @YouTube On the promise of T cell engagers (Twitter) - Jun 22, 2019
- ||| AMG 420 / Amgen
AMG 420 bite for R/R multiple #myeloma. Good results, manageable toxicity. #EHA24 #EHA2019 (Twitter) - Jun 15, 2019
- || bb2121 / bluebird bio, Celgene, AMG 420 / Amgen
I think there were high hopes with Bb2121 but only lasting a year is dissapointing. Do you think in the next few years they'll manage to get these CAR-Ts remaining in the blood continually fighting? Don't know much about AMG 420 tbh. (Twitter) - Jun 7, 2019
- ||| AMG 420 / Amgen
Impressive response with AMG420 BCMA BiTE with 70% ORR (5/10 MRD neg) at the 400ug dose. (Twitter) - Jun 2, 2019
- || AMG 420 / Amgen
Impressive 70% ORR with AMG420 @ the 400 mg dose (Twitter) - Jun 2, 2019
- |||| AMG 420 / Amgen
#ASCO19 Topp: AMG 420, BCMA BiTE, given as CIV 4 wks on 2 wks off like Blin, assoc w CRS but gen low grade, infections problematic (2 grade 5), and peripheral neuropathy a unique DLT (Twitter) - Jun 2, 2019
- ||| AMG 420 / Amgen
AMG420 is much better and promising with its dose escalation cohort than it’s rivals. Why is not it in top 5? I think it deserves that because this car-t really showed car-t can be something in close future in the treatment of Myeloma. (Twitter) - May 30, 2019
- ||| AMG 420 / Amgen
AMG 420 is a BiTE. Not CAR-T. And we already knew it is active at #ASH18 - so this is an update. Not new info for #ASCO19 #ASCO19VR. Here is the abstract https://t.co/cqt3j3qSwN (Twitter) - May 30, 2019
- ||||| AMG 420 / Amgen
Clinical, Residual disease: BCMA TArgeting AMG420 At 400 µg/d, there were 5 minimal residual disease (MRD)-negative sCRs, 1 VGPR, and 1 PR, for a response rate of 7/10 (70%); at Dec datacut, responses lasted for 5.6-10.4 months with 4 patients ongoing on treatment #ASCO19RF #MMSM https://t.co/YVn34id187 (Twitter) - May 24, 2019
- ||| AMG 420 / Amgen
I know it 👍 when it started. Caramba targets slamf7 but I trust Dr. Einsele. I am not a fan of car-t because of its price and effectiveness but AMG420 seems to solve effectiveness part (no idea about price). I know it’s too early to talk but comparing to others, it’s remarkable (Twitter) - May 24, 2019
- || AMG 420 / Amgen
Hi, just to avoid any missunderstanding: AMG 420 is not part of the @CARAMBA_project. These are two different projects / studies. However both are strongly support / hosted by @H_Einsele and @Uni_WUE. (Twitter) - May 24, 2019
- || bb2121 / bluebird bio, Celgene, AMG 420 / Amgen
In my opinion everyone has to agree with 8007 because all thought bb2121’s first results very promising though they’re not! Considering other ones, AMG420 is a dream. Of course it has way to go but it’s a very good point to start. Thank you @H_Einsele @Uni_WUE @CARAMBA_project (Twitter) - May 24, 2019
- |||| Darzalex SC (daratumumab) / J&J, AMG 420 / Amgen
Clinical, Real-World Evidence: #ASCO19Top10 Myeloma #ASCO19OL: 8005: Dara SC. Big! 8007: AMG420. Wow! 8002: FORTE. Agree! 8057: MyDRUG. Forward! e19537: 4-drugs in NDMM. Future! e19525: Blood MRD. Cool! 8051: Ixa in SMM. Weak! 8024: MRD v FISH. Both! e19505: KRd weekly. Nice! 8026: MRD real-world. Yay! #mmsm (Twitter) - May 24, 2019
- |||| iberdomide (CC-220) / Celgene, Darzalex SC (daratumumab) / J&J, AMG 420 / Amgen
My top 10 #ASCO2019 abstracts #mmsm 8007: AMG420 Phase 1 in RRMM 8006: Iberdomide Phase 1/2 in RRMM 8003: VTd +/- Dara in TE NDMM 8005: Dara IV vs Dara SC Phase III 8001: Len vs Obs Phase III in Smoldering MM All TPS except 8052 (need clarity about Ven @ASCO @LevineCancer (Twitter) - May 22, 2019
- || AMG 420 / Amgen
First trials are not promising except amg-420 dose escalation. Impossible to agree to Dr Lonial! (Twitter) - May 18, 2019
- |||| AMG 420 / Amgen
Clinical: #ASCO19top10, #ASCO19OL, Top 10 myeloma abstract: AMG420 BiTE. Based on small numbers, best response rate ever for myeloma drug: 70%! Longterm deep responses. Limited toxicity. @AMGEN pls develop cool personal pump covers! Excellent for patients. The future is already here! #mmsm (Twitter) - May 17, 2019
- ||||| AMG 420 / Amgen
Clinical: Upcoming ASCO19 oral presentation: AMG 420, anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, in relapsed/refractory myeloma: 70% response rate (7/10). 5 patients achieving sCR. Early, exciting data! #mmsm @theMMRF @IMFmyeloma https://t.co/v5Fod7pYa2 (Twitter) - May 16, 2019
- || AMG 420 / Amgen
Than I can only suggest amg-420 car-t because only it has promising results right now. But I have to say, its’ dose escalation is promising, not normal dose! Normal dose is ordinary car-t but dose escalation cohort has %80 sCR and %20CR in 10 months. (Twitter) - May 6, 2019
- | pacanalotamab (AMG 420) / Amgen
Trial completion date, Monotherapy: Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients (clinicaltrials.gov) - Mar 26, 2019
P1, N=43, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Jan 2020 --> Nov 2020
- ||| AMG 420 / Amgen
Anything from AMG-420 or any car-nk in Myeloma? (Twitter) - Mar 25, 2019
- ||| pacanalotamab (AMG 420) / Amgen
Enrollment open, Trial initiation date, Trial primary completion date, Monotherapy: Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Mar 21, 2019
P1b/2, N=120, Recruiting, Sponsor: Amgen
Trial completion date: Jan 2020 --> Nov 2020 Not yet recruiting --> Recruiting | Initiation date: Jul 2019 --> Mar 2019 | Trial primary completion date: Mar 2021 --> Oct 2021
- || pacanalotamab (AMG 420) / Amgen
Enrollment closed, Monotherapy: Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients (clinicaltrials.gov) - Jan 8, 2019
P1, N=50, Active, not recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting | Initiation date: Jul 2019 --> Mar 2019 | Trial primary completion date: Mar 2021 --> Oct 2021 Recruiting --> Active, not recruiting
- | pacanalotamab (AMG 420) / Amgen
Trial completion date, Monotherapy: Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients (clinicaltrials.gov) - May 1, 2018
P1, N=50, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Trial completion date: Dec 2018 --> Oct 2019
- pacanalotamab (AMG 420) / Amgen
Trial primary completion date, Monotherapy: Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients (clinicaltrials.gov) - Jun 8, 2017
P1, N=50, Recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Dec 2018 --> Oct 2019 Trial primary completion date: Jul 2017 --> Jul 2018
- pacanalotamab (AMG 420) / Amgen
Monotherapy: Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients (clinicaltrials.gov) - Sep 20, 2016
P1, N=50, Recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Jul 2017 --> Jul 2018 N=120 --> 50 | Trial primary completion date: Mar 2017 --> Jul 2017
- ||| pacanalotamab (AMG 420) / Amgen
New P1 trial, Monotherapy: Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients (clinicaltrials.gov) - Aug 3, 2015
P1, N=120, Recruiting, Sponsor: Boehringer Ingelheim